Multimodal Platform Fluxergy is building a compact, multimodal point-of-care platform that consolidates molecular, immunochemistry, chemistry, and cytometry tests. This offers cross-selling opportunities to veterinary labs, human clinical labs, and research institutions seeking a unified analyzer to streamline workflows and reduce equipment multiple vendors.

Veterinary Focus Expansion With in-house PCR adoption already active in over 80 veterinary labs and referral centers across US, Canada, and EU, there is a clear entry point to expand sales within veterinary diagnostics, biosecurity, and health monitoring, including potential collaborations with veterinary hospitals and animal health distributors.

Strategic Collaborations Recent NIH collaboration and ongoing academic-industry activity suggest strong demand signals for pathogen detection, NIAID-aligned testing, and diagnostics for infectious diseases. Leverage these relationships to position Fluxergy as a trusted collaborator for grant-funded studies and contract research.

Clinical Lab Outreach Participation in major events like the ADLM Annual Scientific Meeting and Clinical Lab Expo signals active engagement with central labs and clinical researchers. Use these platforms to highlight total-access workflows, cost-per-test reductions, and fast time-to-result advantages to decision-makers in hospital and reference labs.

Financial Leverage With a mid-market size and revenue in the tens of millions supported by a $50M funding base, Fluxergy has room to pursue channel partnerships, distributor networks, and co-development deals to accelerate adoption in mid-tier labs, regional hospitals, and international markets.